January 26, 2023 11:03 AM EST
News Briefing

Evotec inks li­cense agree­ment with J&J; On­colyt­ic virus biotech prices $15M IPO

Paul Schloesser

Associate Editor

Drug dis­cov­ery and de­vel­op­ment play­er Evotec en­tered an­oth­er li­cens­ing deal with Big Phar­ma — this time with J&J’s Janssen.
The com­pa­nies put out

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

A service from the Financial Times